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CD4 subset is the T lymphocyte sub-population that is commonly used in clinical arena for decision making of various conditions \[[@CR1]\]. It is most widely used blood parameters to monitor human immunodeficiency virus (HIV) patients for disease progression, clinical staging, epidemiological studies, and prophylaxis of some opportunistic infection \[[@CR2]\]. CD4 subset tends to decreases with disease progression, leading to relative increase of CD8 T lymphocyte and subsequent reversal of CD4 to CD8 T lymphocyte ratio \[[@CR3]\]. The course of disease is better understood by comparing CD4 count with the available local reference range.

HIV RNA viral load testing is considered gold standard to monitor antiretroviral therapy (ART) response. Despite its high sensitivity, viral load testing has a number of problems in use and, is not feasible in all the settings due to high cost and technical demands \[[@CR4]\]. In such scenario, CD4 T cell count, and clinical monitoring is recommended to monitor the efficacy of antiretroviral therapy, especially in resource-poor settings \[[@CR5]\]. In addition, CD4 count may also be used in decision making for initiation of ART in HIV patients \[[@CR6]\]. National HIV testing and treatment guideline in Nepal suggests CD4 count as one of the baseline test to monitor antiretroviral therapy that has to be checked every 6 months. The further steps on prophylaxis could be taken based on CD4 level along with some other baseline test such as Hemoglobin estimation, Urea and Alanine Aminotransferase \[[@CR6]\]. These all show that CD4 count is necessary to guide antiretroviral therapy and, to decrease the chance for morbidity, mortality and vertical transmission of the disease \[[@CR7]\].

CD4 count testing service was available at eighteen sites across the country till 2014, which reached to thirty by 2017 \[[@CR8]\]. HIV RNA viral load testing was provided only from three centers: National Public Health Laboratory in Kathmandu, Bir Hospital in Kathmandu and Seti Zonal Hospital in Kailali to supplement the ART management program till 2017 \[[@CR9]\]. As Nepal is a developing country with weak economic status, it is difficult to establish viral load testing in all the sites. In such case, management of ART program through CD4 count would be effective in achieving the goal to control the progression of HIV in Nepal.

In the past decade, a number of studies have sought to determine the reference range of CD4 and CD3 count in different parts of the world \[[@CR10]\]. The variation in reference range due to climatic factors, geographical locations, dietary habits, ethnic variation and environmental factors in different studies has already been documented \[[@CR11]--[@CR13]\]. Nepal is a country with wide geographical, climatic and ethnic variation. A study carried out in Eastern, Central and Western Development region of Nepal showed different mean values for CD4 count \[[@CR1]\]. Because Nepal has a wide ethnic and climatic variation, regional as well as national reference range seems important. Reference range of CD4 had been established in Eastern, Central and Western development region of Nepal while the same is still to be established in Mid-western and Far-western development region of the country. This study was carried out with the objective of establishing regional reference range of CD4 T lymphocyte count as well as national reference range with the help of data from previous study in Nepal.

Main text {#Sec2}
=========
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-------

A descriptive cross-sectional study was carried out among healthy adult population in mid-western and far-western development region of Nepal from March to May 2016. Samples were collected from healthy volunteers willing to participate in the study after filling questionnaire form. The form was filled by face-to-face interview for each participant. The basic information included in the form was: name, age, sex and, history of acute or chronic disease. Only the healthy adults of 15--60 years with no previous history of any kind of diseases, recent medication or blood transfusion were included in the study. Women in the pregnancy period were excluded from the study (Additional file [1](#MOESM1){ref-type="media"}). The collected samples were tested for the presence of HIV antibodies. Among the HIV sero-negative healthy volunteers, 400 were selected for study (200 in each site). The selected samples were processed for further laboratory analysis at two major government based hospitals; Bheri zonal hospital and Seti zonal hospital. The sample size was in accordance to the CLSI guidelines for determining laboratory reference ranges which indicates a minimum of 153 subjects to be enrolled in the study for 95th percentile value with 95% confidence interval \[[@CR14]\]. The sample was collected in between 10.00 AM to 2.00 PM to minimize the diurnal variation. To obtain homogeneity in data, participants from different districts of the region were included. In addition, enrollment of both sex, and adults from different age group were also considered to eliminate the possible bias.

About 3 ml whole blood sample was collected in tripotassium ethylenediaminetetraacetic acid (K3EDTA) vial from the healthy volunteers participating in study. All the samples were tested for the presence of HIV antibodies following national algorithm that includes HIV1/2 rapid test assay using three different commercial kits: Determine, Stat-Pak and Uni-Gold. HIV negative samples were assayed for CD3 and CD4 T lymphocyte count.

T lymphocyte count was carried out using BD FACS Calibur (BD Biosciences, San Jose, CA, USA) following manufacturer's instructions. Briefly, 50 μl of well-mixed EDTA whole blood was pipetted into a BD Trucount tube containing bead. 20 μl of BD Tritest™ CD3/CD4/CD45 reagent containing monoclonal antibodies for CD3, CD4 and CD45, labeled with fluorescent dyes was also added to the same tube. The tube was then vortexed, and incubated in dark at room temperature for 15 min to stain the cells. Following staining, red blood cells were lysed using BD FACS lysing solution and run in the flow cytometer to obtain absolute count.

For the purpose of quality control, calibration beads were run every day to ensure the optical alignment of the instrument following compensation setting using the software. Internal quality control was also run at both the centers using commercially available stabilized blood samples. Samples were run only when the result of internal quality control was within the range of the value provided by the manufacturer.

Data collected were initially entered into MS Excel, which was then transferred to Statistical Package for Social Sciences (SPSS) and analyzed using the same SPSS version 20.0 \[IBM Armonk, NY, USA\]. Mean, median and standard deviation values were calculated for each parameter. Wilks-Shapiro test was used to understand the distribution of data, which showed significant difference suggesting non-Gaussian distribution. Based on this, the decision for non-parametric analysis was made to establish the reference range. The reference range was defined as the central 95% of the area under the distribution curve of the values (from 2.5% to 97.5%). ANOVA test was used to compare mean between variables considering 95% CI and, p value less than 0.05 was considered statistically significant.

Results {#Sec4}
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A total of 400 healthy adults (157 females and 243 males) were enrolled in study with the ratio of female to male, 1:1.5. Age of the participants included in the study range from 15--60 years with the mean age of 27 years. The overall mean, standard deviation and 95% CI were obtained for both CD4 and CD3 T lymphocyte. The data showed that both the CD4 (p-value 0.000) and CD3 (p-value 0.000) values were significantly different in male compared to female. Male had lower value for both CD4 (757 ± 270) and CD3 (1465 ± 499) in comparison to female, CD4 (914 ± 303) and CD3 (1671 ± 560) (Table [1](#Tab1){ref-type="table"}).Table 1T lymphocytes subset in different age groups and sex (N = 400)VariablesMean ± SDSE95% CIMinimumMaximump-valueCD3 Sex  Male1465 ± 49932.01402--15285103091*0.000*  Female1671 ± 56044.71582--17596353737 Age group  15--291549 ± 49329.21492--160751032280.960  30--441533 ± 63764.61404--16616123737  45--591559 ± 544124.81297--18226752888  Sub-total1546 ± 53226.61494--15985103737CD4 Sex  Male757 ± 27017.3723--7913101754*0.000*  Female914 ± 30324.2867--9623061917 Age group  15--29817 ± 28016.6784--85030617560.795  30--44814 ± 32733.1749--8813281917  45--59863 ± 32875.3705--10213761754  Sub-total819 ± 29414.7790--8483061917

Most of the participants had absolute CD4 T lymphocyte count in between 500 and 1000 cells/μl (65.25%) followed by 1000--1500 cells/μl (18.5%), \< 500 cells/μl (13.0%) and \> 1500 cells/μl (3.25%). The reference range for CD4 (380--1553 cells/μl) and CD3 (743--2803 cells/μl) were determined in participants from western Nepal. Because male and female had significantly different mean values for both CD4 and CD3 T lymphocyte, the reference range was determined separately for male and female. Reference range of CD4 was (344--1470) cells/μl for male and (393--1599) cells/μl for female. Likewise, reference range of CD3 was (753--2762) cells/μl for male and (737--3241) cells/μl for female. In addition, reference range for CD4 and CD3 were also calculated separately in Mid-western development region and Far-western development region of the country (Table [2](#Tab2){ref-type="table"}). The national reference range of CD4 T lymphocyte was determined to be (798 ± 335) cells/μl (Table [3](#Tab3){ref-type="table"}).Table 2Absolute CD4 count in healthy Nepalese adult from western NepalMid-western region (N = 200)Far-western region (N = 200)Total (N = 400)Mean±SDMedian2.5th --97.5th PercentileMean±SDMedian2.5th--97.5th PercentileMean±SDMedian2.5th --97.5th PercentileCD4 Male744 ± 274689337--1626768 ± 268736386--1467757 ± 270716344--1470 Female830 ± 267815388--15461014 ± 315969467--1784914 ± 303870393--1599 Sub-total780 ± 273753341--1552857 ± 309809396--1560819 ± 294785380--1553CD3 Male1427 ± 4921347676--27941500 ± 5041410794--27541465 ± 4991381753--2762 Female1481 ± 4141491699--23871894 ± 6261857904--35321671 ± 5601562737--3241 Sub-total1450 ± 4601390693--25231642 ± 5811526820--31141546 ± 5321468743--2803Table 3Mean CD4 count in normal healthy individuals from different countries/populationCountries/populationAbsolute CD4 (Mean ± SD)ReferencesMexico(800 ± 230) cells/μl\[[@CR16]\]Indonesia(753 ± 270) cells/μl\[[@CR17]\]England(830 ± 290) cells/μl\[[@CR18]\]Nigeria(847 ± 307) cells/μl\[[@CR19]\]Tanzania(745 ± 256) cells/μl\[[@CR11]\]India(919 ± 311) cells/μl\[[@CR10]\]Turkey(1095 ± 391) cells/μl\[[@CR21]\]South Indians1048 cells/μl\[[@CR20]\]China(727 ± 255) cells/μl\[[@CR2]\]Ethiopia660,775 (Median)\[[@CR22], [@CR28]\]Uganda836, 838,1256 (Median)\[[@CR22], [@CR24]\]Nepal Eastern715 ± 234\[[@CR1]\] Central835 ± 306 Western807 ± 167 Mid-western region780 ± 273Present study Far-western region857 ± 309 National reference value798 ± 335Present study and (1)

Discussion {#Sec5}
==========

CD4 T lymphocyte is an essential marker in guiding clinical decisions regarding disease staging and therapeutic monitoring in case of HIV infection \[[@CR6], [@CR15]\]. In order to establish the reference range of T lymphocyte count employed, unemployed and students of adult age group were selected from different districts without bias. Furthermore, participants from different ethnic groups, geographical area and gender were also enrolled to eliminate the possible bias.

The mean value of absolute CD4 count obtained in this study, (819 ± 294) cells/μl is comparable to the previous study by Shakya et al. carried out in three development regions of Nepal \[[@CR1]\]. The result is also similar to the studies from Mexico city (800 ± 230), Indonesia (753 ± 270), England (830 ± 290), Nigeria (847 ± 307) and Tanzania (745 ± 256) \[[@CR11], [@CR16]--[@CR19]\]. However, the CD4 mean value obtained in our study is comparatively lower than those from India (919 ± 311), Turkey (1095 ± 391) and South India (1048) and, higher than Chinese adults (727 ± 255) \[[@CR2], [@CR10], [@CR20], [@CR21]\] (Table [3](#Tab3){ref-type="table"}). The Saharan African population had a diverse distribution of CD4 counts from Ethiopia (660) to Uganda (1256) \[[@CR22]--[@CR24]\]. The deviation of mean CD4 count in population from different geographical area might be due to different methodology employed for the study. Also, it seems likely that these results are in fact due to multiple factors such as lifestyle and ethnic variations in populations from different parts of the world.

The present study obtained higher value of CD4 and CD3 T lymphocyte for female compared to male. This is comparable to that of the previous study by Shakya et al. in three development region (Eastern, Central and Western) of Nepal \[[@CR1]\]. The higher CD4 count among female was also documented by the study of Grinsztejn et al. and Lee et al. \[[@CR25], [@CR26]\]. The possible explanation for such a result might be the influence of sex hormones on immunity that is responsible for higher CD4 count in female \[[@CR22], [@CR27]\]. Since the present study obtained significantly different values of absolute CD4 and CD3 T lymphocyte count in male and female population, it was felt appropriate to establish separate reference range for male and female. The reference range of CD4 T lymphocyte was determined to be (344--1470) cells/μl for male and (393--1599) cells/μl for female. Similarly, the reference range of CD3 T lymphocyte was calculated to be (753--2762) cells/μl for male and (737--3241) cells/μl for female.

There are large numbers of ethnic groups residing throughout the country with different socio-economic status. Few ethnic groups are found living in particular geographical area and have distinct lifestyle. A previous study in 2012 by Shakya et al. established the reference range in Eastern, Central and Western development region of the country \[[@CR1]\]. This study has determined reference range in remaining two development regions; Mid-western and Far-western development regions. When we combine the data from the study of Shakya et al. and the present study, we obtain the mean average absolute CD4 T cell count 798 ± 335 cells/μl that can be taken as the national reference value for Nepalese healthy adults (Table [3](#Tab3){ref-type="table"}).

Conclusion {#Sec6}
==========

The study established the reference range of CD4 and CD3 T lymphocyte count in healthy adults from western part of Nepal and determined the national reference value of CD4 T cell. It also suggests using separate values of reference range for male and female population.

Limitation {#Sec7}
==========

We combined the result of two study carried out at different interval of time; first in year 2009 and the next in year 2016 to include the data from different parts of the country for establishment of national reference range of CD4 T lymphocyte count.
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**Additional file 1:** Questionnaire form for participating individuals. The data in the form is a set of questions to be asked by a health worker to the participating volunteers to access their health status along with other information.

ART

:   Antiretroviral therapy

HIV

:   Human immunodeficiency virus

CD

:   Cluster of Differentiation

RNA

:   Ribonucleic Acid

CLSI

:   Clinical and Laboratory Standards Institute

EDTA

:   Ethylenediaminetetraacetic acid

NPHL

:   National Public Health Laboratory
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